Nina Øyen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nina Øyen has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Charlotta Granström
Department of Epidemiology Research Statens Serum Institut Copenhagen Denmark
1 shared publicationElisabeth Leirgul
Department of Global Public Health and Primary Care University of Bergen Norway
1 shared publication- Elisabeth Leirgul
Affiliation Haukeland University Hospital, Bergen, Norway
1 shared publication - Gottfried Greve
Affiliations Haukeland University Hospital, Bergen, Norway, University of Bergen, Bergen, Norway
1 shared publication Grethe S. Tell
Department of Global Public Health and Primary Care University of Bergen Norway
1 shared publication- Grethe Seppola Tell
Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway
1 shared publication
Latest Publications
- 21 July 2025
- Published by Wiley in Acta Paediatrica
- Vol. 114 (12) , 3199-3208
Trends in Birth Prevalence of Congenital Heart Defects in Norway—A Population Study 1994–2014
Aim: The prevalence of severe congenital heart defects (CHDs) has been declining in Europe, possibly because pregnancies with foetal anomalies are often terminated. We present trends in the prevalence of CHD among live births, stillbirths and terminated pregnancies over a 21‐year period in Norway. Method: All births and terminated pregnancies registered in Norway's Medical Birth Registry from 1994–2014 were linked to information on CHDs and extracardiac birth defects or chromosomal aberrations found in national administrative and clinical registries. Results: We identified 18 838 individuals with CHD among the 1 261 952 live births, stillbirths and terminated pregnancies, which was 149.3 per 10 000. In live births, the CHD prevalence was 144.6 per 10 000. The prevalence of severe CHD increased from 27.1 in 1994 to 36.1 in 2004, then declined to 27.8 in 2014, with an overall prevalence of 32.1 per 10 000. In live births, the prevalence was 29.0 per 10 000. The prevalence of severe CHD in nonsyndromic births was 20.4 per 10 000, with no time trend. Septal defects increased continuously after 1994. Conclusion: From 2004–2014, the prevalence of severe CHD declined, primarily due to a decrease in syndromic CHD. This could likely be explained by pregnancy terminations. Septal defects increased over the entire study period.
- 21 July 2025
- Published by Wiley in Acta Paediatrica
- Vol. 114 (12) , 3199-3208
Trends in Birth Prevalence of Congenital Heart Defects in Norway—A Population Study 1994–2014
Aim: The prevalence of severe congenital heart defects (CHDs) has been declining in Europe, possibly because pregnancies with foetal anomalies are often terminated. We present trends in the prevalence of CHD among live births, stillbirths and terminated pregnancies over a 21‐year period in Norway. Method: All births and terminated pregnancies registered in Norway's Medical Birth Registry from 1994–2014 were linked to information on CHDs and extracardiac birth defects or chromosomal aberrations found in national administrative and clinical registries. Results: We identified 18 838 individuals with CHD among the 1 261 952 live births, stillbirths and terminated pregnancies, which was 149.3 per 10 000. In live births, the CHD prevalence was 144.6 per 10 000. The prevalence of severe CHD increased from 27.1 in 1994 to 36.1 in 2004, then declined to 27.8 in 2014, with an overall prevalence of 32.1 per 10 000. In live births, the prevalence was 29.0 per 10 000. The prevalence of severe CHD in nonsyndromic births was 20.4 per 10 000, with no time trend. Septal defects increased continuously after 1994. Conclusion: From 2004–2014, the prevalence of severe CHD declined, primarily due to a decrease in syndromic CHD. This could likely be explained by pregnancy terminations. Septal defects increased over the entire study period.
- Open Access
- 24 May 2022
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 15 (4) , 287-294
Risk of Congenital Heart Defects in Offspring of Affected Mothers and Fathers
Background: Smaller studies have reported a higher offspring risk of congenital heart defects (CHDs) for mothers with CHDs than for fathers with CHDs. In a large population-based study, we investigated whether offspring risk of CHD differed for mothers and fathers with CHDs. Methods: All people born in Denmark, 1977 to 2011, with at least 1 registered parent, were included in our cohort (n=2 341 061). Parent-child recurrence of CHDs was evaluated using risk ratios (RRs) comparing risks of CHDs in individuals with and without a parent with a CHD, estimated using log-linear binomial regression. Results: The RRs for any CHD in offspring were 5.39 (95% CI, 4.88–5.96) for mothers and 3.04 (95% CI, 2.59–3.57) for fathers affected with any CHD; the ratio of RRs for mothers versus fathers was 1.82 ( P <0.0001). Recurrence RRs for the same cardiac phenotype in parent and offspring were significantly stronger for mothers than for fathers for conotruncal defects (ratio of RRs, 4.98), left ventricular outlet tract obstruction (ratio of RRs, 4.98), and ventricular septal defects (ratio of RRs, 2.51) but not for atrioventricular septal defects (ratio of RRs, 1.06). Birth rates among people with CHDs, relative to the general population, were 18% higher for women than for men, regardless of parental cardiac phenotype. Conclusions: Recurrence risks of CHDs were significantly greater in the offspring of affected women than in the offspring of affected men. The excess maternal recurrence risks could not be explained by the slightly higher birth rates in women with CHDs.
- 24 May 2022
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 15 (4) , 287-294
Open AccessRisk of Congenital Heart Defects in Offspring of Affected Mothers and Fathers
Background: Smaller studies have reported a higher offspring risk of congenital heart defects (CHDs) for mothers with CHDs than for fathers with CHDs. In a large population-based study, we investigated whether offspring risk of CHD differed for mothers and fathers with CHDs. Methods: All people born in Denmark, 1977 to 2011, with at least 1 registered parent, were included in our cohort (n=2 341 061). Parent-child recurrence of CHDs was evaluated using risk ratios (RRs) comparing risks of CHDs in individuals with and without a parent with a CHD, estimated using log-linear binomial regression. Results: The RRs for any CHD in offspring were 5.39 (95% CI, 4.88–5.96) for mothers and 3.04 (95% CI, 2.59–3.57) for fathers affected with any CHD; the ratio of RRs for mothers versus fathers was 1.82 ( P <0.0001). Recurrence RRs for the same cardiac phenotype in parent and offspring were significantly stronger for mothers than for fathers for conotruncal defects (ratio of RRs, 4.98), left ventricular outlet tract obstruction (ratio of RRs, 4.98), and ventricular septal defects (ratio of RRs, 2.51) but not for atrioventricular septal defects (ratio of RRs, 1.06). Birth rates among people with CHDs, relative to the general population, were 18% higher for women than for men, regardless of parental cardiac phenotype. Conclusions: Recurrence risks of CHDs were significantly greater in the offspring of affected women than in the offspring of affected men. The excess maternal recurrence risks could not be explained by the slightly higher birth rates in women with CHDs.
- Open Access
- 19 March 2019
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 8 (6) , e011615
Association Between Maternal Folic Acid Supplementation and Congenital Heart Defects in Offspring in Birth Cohorts From Denmark and Norway
Background: Evidence linking individual‐level maternal folic acid supplementation to offspring risk of congenital heart defects is lacking. We investigated whether folic acid supplementation in early pregnancy reduces offspring risk of heart defects in 2 large birth cohort studies. Methods and Results: Women recruited in early pregnancy within the DNBC (Danish National Birth Cohort), 1996–2003, and MoBa (Norwegian Mother and Child Cohort Study), 2000–2009, were followed until delivery. Information on periconceptional intake of folic acid and other supplements was linked with information on heart defects from national registers. Among 197 123 births, we identified 2247 individuals with heart defects (114/10 000). Periconceptional (4 weeks before through 8 weeks after conception) use of folic acid plus other supplements (54.8%), folic acid only (12.2%), and non–folic acid supplements (5.0%) were compared with no supplement use (28.0%); the adjusted relative risks of heart defects were 0.99 (95% CI, 0.80–1.22), 1.08 (95% CI , 0.93–1.25), and 1.07 (95% CI , 0.97–1.19), respectively. For initiation of folic acid in the preconception period weeks −4 to −1 (33.7%) and the postconception periods 0 to 4 weeks (15.5%), 5 to 8 weeks (17.8%), and 9 to 12 weeks (4.6%), compared with no or late folic acid intake (29.1%), relative risks of heart defect were 1.11 (95% CI , 1.00–1.25), 1.09 (95% CI , 0.95–1.25), 0.98 (95% CI , 0.86–1.12), and 0.97 (95% CI , 0.78–1.20), respectively. Relative risks of severe defects, conotruncal defects, and septal defects showed similar results. Conclusions: Folic acid was not associated with offspring risk of heart defects, including severe defects, conotruncal defects, or septal defects.
- 19 March 2019
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 8 (6) , e011615
Open AccessAssociation Between Maternal Folic Acid Supplementation and Congenital Heart Defects in Offspring in Birth Cohorts From Denmark and Norway
Background: Evidence linking individual‐level maternal folic acid supplementation to offspring risk of congenital heart defects is lacking. We investigated whether folic acid supplementation in early pregnancy reduces offspring risk of heart defects in 2 large birth cohort studies. Methods and Results: Women recruited in early pregnancy within the DNBC (Danish National Birth Cohort), 1996–2003, and MoBa (Norwegian Mother and Child Cohort Study), 2000–2009, were followed until delivery. Information on periconceptional intake of folic acid and other supplements was linked with information on heart defects from national registers. Among 197 123 births, we identified 2247 individuals with heart defects (114/10 000). Periconceptional (4 weeks before through 8 weeks after conception) use of folic acid plus other supplements (54.8%), folic acid only (12.2%), and non–folic acid supplements (5.0%) were compared with no supplement use (28.0%); the adjusted relative risks of heart defects were 0.99 (95% CI, 0.80–1.22), 1.08 (95% CI , 0.93–1.25), and 1.07 (95% CI , 0.97–1.19), respectively. For initiation of folic acid in the preconception period weeks −4 to −1 (33.7%) and the postconception periods 0 to 4 weeks (15.5%), 5 to 8 weeks (17.8%), and 9 to 12 weeks (4.6%), compared with no or late folic acid intake (29.1%), relative risks of heart defect were 1.11 (95% CI , 1.00–1.25), 1.09 (95% CI , 0.95–1.25), 0.98 (95% CI , 0.86–1.12), and 0.97 (95% CI , 0.78–1.20), respectively. Relative risks of severe defects, conotruncal defects, and septal defects showed similar results. Conclusions: Folic acid was not associated with offspring risk of heart defects, including severe defects, conotruncal defects, or septal defects.
- Open Access
- 30 May 2018
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 18 (1) , 188
Paternal characteristics associated with maternal periconceptional use of folic acid supplementation
Maternal predictors of folic acid (FA) supplementation use to reduce offspring risk of neural tube defects are well known, while paternal determinants for maternal FA use are less known. Such knowledge is important to increase women’s compliance to recommended periconceptional FA use. In a nation-wide study of 683,785 births registered in the Medical Birth Registry of Norway during 1999–2010, the associations between paternal characteristics (age, education, occupation, country of origin) and maternal FA use were estimated by relative risks (RR) with 95% confidence intervals (CI), using log-binomial regression. Maternal FA use before and during pregnancy (adequate FA use) was found in 16% of the births. The association between paternal age and adequate FA use was inversely U-shaped; adjusted RRs for adequate FA use were 0.35 (95% CI 0.28–0.43) and 0.72 (95% CI 0.71–0.74) for paternal age < 20 and ≥ 40 years, respectively, comparing age 30–34 years. Compulsory education (1–9 years) among fathers was compared to tertiary education; the RR was 0.69 (95% CI 0.68–0.71) for adequate FA use. The lower risk of adequate FA use for paternal compulsory education was present in all categories of maternal education. Occupation classes other than “Higher professionals” were associated with decreased risk of adequate FA use, compared with the reference “Lower professionals”. RR for adequate FA use was 0.58 (95% CI 0.56–0.60) comparing fathers from “Low/middle-income countries” with fathers born in Norway. Adequate FA use in the periconceptional period was lower when fathers were younger or older than 30–34 years, had shorter education, had manual or self-employed occupations, or originated from low/middle-income countries. Partners may contribute to increase women’s use of periconceptional FA supplementation.
- 30 May 2018
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 18 (1) , 188
Open AccessPaternal characteristics associated with maternal periconceptional use of folic acid supplementation
Maternal predictors of folic acid (FA) supplementation use to reduce offspring risk of neural tube defects are well known, while paternal determinants for maternal FA use are less known. Such knowledge is important to increase women’s compliance to recommended periconceptional FA use. In a nation-wide study of 683,785 births registered in the Medical Birth Registry of Norway during 1999–2010, the associations between paternal characteristics (age, education, occupation, country of origin) and maternal FA use were estimated by relative risks (RR) with 95% confidence intervals (CI), using log-binomial regression. Maternal FA use before and during pregnancy (adequate FA use) was found in 16% of the births. The association between paternal age and adequate FA use was inversely U-shaped; adjusted RRs for adequate FA use were 0.35 (95% CI 0.28–0.43) and 0.72 (95% CI 0.71–0.74) for paternal age < 20 and ≥ 40 years, respectively, comparing age 30–34 years. Compulsory education (1–9 years) among fathers was compared to tertiary education; the RR was 0.69 (95% CI 0.68–0.71) for adequate FA use. The lower risk of adequate FA use for paternal compulsory education was present in all categories of maternal education. Occupation classes other than “Higher professionals” were associated with decreased risk of adequate FA use, compared with the reference “Lower professionals”. RR for adequate FA use was 0.58 (95% CI 0.56–0.60) comparing fathers from “Low/middle-income countries” with fathers born in Norway. Adequate FA use in the periconceptional period was lower when fathers were younger or older than 30–34 years, had shorter education, had manual or self-employed occupations, or originated from low/middle-income countries. Partners may contribute to increase women’s use of periconceptional FA supplementation.